Skip to main content
NCBI home page
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1990;68(3):313–322.

Malaria chemoprophylaxis among European tourists in tropical Africa: use, adverse reactions, and efficacy.

R Steffen 1, R Heusser 1, R Mächler 1, R Bruppacher 1, U Naef 1, D Chen 1, A M Hofmann 1, B Somaini 1
PMCID: PMC2393070  PMID: 2393977

Abstract

In order to determine knowledge, attitudes and practices towards malaria prophylaxis, as well as its side-effects and efficacy, a self-administered questionnaire was distributed to European travellers on return flights from tropical Africa to Europe. Between 1985 and 1988 the questionnaire was completed by 44,472 passengers (80.1% of those on board) on 242 flights. A follow-up questionnaire was completed by 42,202 (94.9%) of the same travellers 3 months later. Almost all knew about the risk of malaria, but 10% relied solely on advice from nonmedical sources. While 55.6% had taken at least one measure against mosquito bites, only 4.5% adopted three such measures (used repellents and insecticides and wore long clothing after dusk). Compliance with chemoprophylaxis use was reported by 57.0% of travellers who spent less than 3 months in Africa, compared with 29.2% who stayed 3-12 months. Depending on the antimalaria regimen taken, 11-44% of the travellers experienced adverse effects, while four deaths were attributed to the chemoprophylaxis. The incidence of malaria per month of exposure for travellers who took no chemoprophylaxis was 15.2 per 1000 in East Africa and 24.2 per 1000 in West Africa. In East Africa, the prophylactic efficacy of the currently recommended antimalaria regimens (relative to that of no chemoprophylaxis) was zero for a chloroquine dosage of 300 mg base per week (4 malaria fatalities), 64.1% for a chloroquine dosage of 600 mg base per week (P = 0.03), and 94.0% for mefloquine (P = 0.003).

Full text

PDF
313

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bernuau J., Larrey D., Campillo B., Degott C., Verdier F., Rueff B., Pessayre D., Benhamou J. P. Amodiaquine-induced fulminant hepatitis. J Hepatol. 1988 Feb;6(1):109–112. doi: 10.1016/s0168-8278(88)80469-0. [DOI] [PubMed] [Google Scholar]
  2. Campbell H., Byass P., Greenwood B. M. Bed-nets and malaria suppression. Lancet. 1987 Apr 11;1(8537):859–860. doi: 10.1016/s0140-6736(87)91633-3. [DOI] [PubMed] [Google Scholar]
  3. Danis M., Diquet B., Turk P., Brousse G., Bretagne S., Dufourg P. Pharmacocinétique de la chloroquine à doses prophylactiques chez 10 volontaires sains. Résultats préliminaires. Bull Soc Pathol Exot Filiales. 1985;78(5 Pt 2):953–958. [PubMed] [Google Scholar]
  4. Good M. I., Shader R. I. Behavioral toxicity and equivocal suicide associated with chloroquine and its derivatives. Am J Psychiatry. 1977 Jul;134(7):798–601. doi: 10.1176/ajp.134.7.798. [DOI] [PubMed] [Google Scholar]
  5. Good M. I., Shader R. I. Lethality and behavioral side effects of chloroquine. J Clin Psychopharmacol. 1982 Feb;2(1):40–47. doi: 10.1097/00004714-198202000-00005. [DOI] [PubMed] [Google Scholar]
  6. Karch F. E., Lasagna L. Adverse drug reactions. A critical review. JAMA. 1975 Dec 22;234(12):1236–1241. [PubMed] [Google Scholar]
  7. Krogstad D. J., Gluzman I. Y., Kyle D. E., Oduola A. M., Martin S. K., Milhous W. K., Schlesinger P. H. Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance. Science. 1987 Nov 27;238(4831):1283–1285. doi: 10.1126/science.3317830. [DOI] [PubMed] [Google Scholar]
  8. Lobel H. O., Campbell C. C., Pappaioanou M., Huong A. Y. Use of prophylaxis for malaria by American travelers to Africa and Haiti. JAMA. 1987 May 15;257(19):2626–2627. [PubMed] [Google Scholar]
  9. Lobel H. O., Campbell C. C., Roberts J. M. Fatal malaria in US civilians. Lancet. 1985 Apr 13;1(8433):873–873. doi: 10.1016/s0140-6736(85)92232-9. [DOI] [PubMed] [Google Scholar]
  10. Lobel H. O., Phillips-Howard P. A., Brandling-Bennett A. D., Steffen R., Campbell C. C., Huong A. Y., Were J. B., Moser R. Malaria incidence and prevention among European and North American travellers to Kenya. Bull World Health Organ. 1990;68(2):209–215. [PMC free article] [PubMed] [Google Scholar]
  11. Lobel H. O., Roberts J. M., Somaini B., Steffen R. Efficacy of malaria prophylaxis in American and Swiss travelers to Kenya. J Infect Dis. 1987 Jun;155(6):1205–1209. doi: 10.1093/infdis/155.6.1205. [DOI] [PubMed] [Google Scholar]
  12. Miller K. D., Lobel H. O., Satriale R. F., Kuritsky J. N., Stern R., Campbell C. C. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg. 1986 May;35(3):451–458. doi: 10.4269/ajtmh.1986.35.451. [DOI] [PubMed] [Google Scholar]
  13. Neftel K. A., Woodtly W., Schmid M., Frick P. G., Fehr J. Amodiaquine induced agranulocytosis and liver damage. Br Med J (Clin Res Ed) 1986 Mar 15;292(6522):721–723. doi: 10.1136/bmj.292.6522.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Nevill C. G., Watkins W. M., Carter J. Y., Munafu C. G. Comparison of mosquito nets, proguanil hydrochloride, and placebo to prevent malaria. BMJ. 1988 Aug 6;297(6645):401–403. doi: 10.1136/bmj.297.6645.401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pang L. W., Limsomwong N., Boudreau E. F., Singharaj P. Doxycycline prophylaxis for falciparum malaria. Lancet. 1987 May 23;1(8543):1161–1164. doi: 10.1016/s0140-6736(87)92141-6. [DOI] [PubMed] [Google Scholar]
  16. Peto T. E., Gilks C. F. Strategies for the prevention of malaria in travellers: comparison of drug regimens by means of risk-benefit analysis. Lancet. 1986 May 31;1(8492):1256–1261. doi: 10.1016/s0140-6736(86)91395-4. [DOI] [PubMed] [Google Scholar]
  17. Phillips-Howard P. A., Radalowicz A., Mitchell J., Bradley D. J. Risk of malaria in British residents returning from malarious areas. BMJ. 1990 Feb 24;300(6723):499–503. doi: 10.1136/bmj.300.6723.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Phillips-Howard P. A., West L. J. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med. 1990 Feb;83(2):82–85. doi: 10.1177/014107689008300208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Steffen R., Somaini B. Severe cutaneous adverse reactions to sulfadoxine-pyrimethamine in Switzerland. Lancet. 1986 Mar 15;1(8481):610–610. doi: 10.1016/s0140-6736(86)92825-4. [DOI] [PubMed] [Google Scholar]
  20. Stürchler D., Schär M., Gyr N. Leucopenia and abnormal liver function in travellers on malaria chemoprophylaxis. J Trop Med Hyg. 1987 Oct;90(5):239–243. [PubMed] [Google Scholar]
  21. Venning G. R. Identification of adverse reactions to new drugs. IV--Verification of suspected adverse reactions. Br Med J (Clin Res Ed) 1983 Feb 12;286(6364):544–547. doi: 10.1136/bmj.286.6364.544. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES